Study the Physiological and Biochemical Effects of Berberine Extract on Nonalcoholic Fatty Liver Disease (NAFLD) in Male Rabbits

H.H.K. Al-Shukri, Areej Gh Al-Charak, R. Abd, Tiba H. Salih, Noora H. Ali, Haneen H. Ghazi, Dunia M. Al-Rubaie, Mohammad H. Mohsen
{"title":"Study the Physiological and Biochemical Effects of Berberine Extract on Nonalcoholic Fatty Liver Disease (NAFLD) in Male Rabbits","authors":"H.H.K. Al-Shukri, Areej Gh Al-Charak, R. Abd, Tiba H. Salih, Noora H. Ali, Haneen H. Ghazi, Dunia M. Al-Rubaie, Mohammad H. Mohsen","doi":"10.36346/sarjps.2024.v06i03.001","DOIUrl":null,"url":null,"abstract":"Nonalcoholic fatty liver disease (NAFLD) is a prevalent global health issue, characterized by hepatic steatosis and associated with metabolic comorbidities such as obesity, diabetes, and dyslipidemia. Berberine (BBR), an isoquinoline alkaloid, has emerged as a potential therapeutic agent for NAFLD. In this research, we evaluated the effects of BBR on NAFLD management and its associated complications. Our analysis included three groups involving 10 rabbits induced NAFLD by administration cholesterol rich diet, 10 rabbits administrated high rich diet with fats and cholesterol, and 10 rabbits with normal fed as control group. BBR demonstrated significant improvements in liver function biochemical markers (ALT, AST, GGT), lipid indices (TC, TG, LDL-C, HDL-C), and physiological parameters such as insulin sensitivity (HOMA-IR) and body mass index (BMI). Importantly, BBR exhibited a favorable safety profile, with minimal gastrointestinal adverse events reported. These findings highlight BBR potential as an adjunct therapy for NAFLD. However, further well-designed clinical trials involving human subjects are warranted to validate its efficacy and safety.","PeriodicalId":244449,"journal":{"name":"South Asian Research Journal of Pharmaceutical Sciences","volume":"6 11","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"South Asian Research Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36346/sarjps.2024.v06i03.001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a prevalent global health issue, characterized by hepatic steatosis and associated with metabolic comorbidities such as obesity, diabetes, and dyslipidemia. Berberine (BBR), an isoquinoline alkaloid, has emerged as a potential therapeutic agent for NAFLD. In this research, we evaluated the effects of BBR on NAFLD management and its associated complications. Our analysis included three groups involving 10 rabbits induced NAFLD by administration cholesterol rich diet, 10 rabbits administrated high rich diet with fats and cholesterol, and 10 rabbits with normal fed as control group. BBR demonstrated significant improvements in liver function biochemical markers (ALT, AST, GGT), lipid indices (TC, TG, LDL-C, HDL-C), and physiological parameters such as insulin sensitivity (HOMA-IR) and body mass index (BMI). Importantly, BBR exhibited a favorable safety profile, with minimal gastrointestinal adverse events reported. These findings highlight BBR potential as an adjunct therapy for NAFLD. However, further well-designed clinical trials involving human subjects are warranted to validate its efficacy and safety.
研究小檗碱提取物对雄性家兔非酒精性脂肪肝(NAFLD)的生理生化影响
非酒精性脂肪肝(NAFLD)是全球普遍存在的健康问题,其特点是肝脏脂肪变性,并伴有肥胖、糖尿病和血脂异常等代谢并发症。小檗碱(BBR)是一种异喹啉生物碱,已成为治疗非酒精性脂肪肝的潜在药物。在这项研究中,我们评估了小檗碱对非酒精性脂肪肝治疗及其相关并发症的影响。我们的分析包括三组兔子,分别为 10 只通过富含胆固醇饮食诱发非酒精性脂肪肝的兔子、10 只通过高脂肪和高胆固醇饮食诱发非酒精性脂肪肝的兔子,以及 10 只正常饮食的兔子作为对照组。BBR 对肝功能生化指标(ALT、AST、GGT)、血脂指标(TC、TG、LDL-C、HDL-C)以及胰岛素敏感性(HOMA-IR)和体重指数(BMI)等生理指标均有明显改善。重要的是,BBR 具有良好的安全性,胃肠道不良反应极少。这些发现凸显了 BBR 作为非酒精性脂肪肝辅助疗法的潜力。不过,要验证其疗效和安全性,还需要进一步开展设计良好的人体临床试验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信